Silexion (SLXN) completes SIL204 tox studies for Phase 2/3 trial

Silexion Therapeutics Corp (SLXN) announced that it has successfully completed toxicology studies for SIL204, its next-generation RNA silencing therapy.

Rhea-AI Filing Summary

Silexion Therapeutics Corp (SLXN) announced that it has successfully completed toxicology studies for SIL204, its next-generation RNA silencing therapy. These studies are a key safety step that supports moving SIL204 into a planned Phase 2/3 clinical trial in pancreatic cancer, a disease with limited treatment options. The update was provided through a press release that is included as an exhibit to this report.

The company’s ordinary shares and related warrants continue to trade on The Nasdaq Stock Market under the symbols SLXN and SLXNW, respectively. The disclosure is furnished under Regulation FD, meaning it is intended to provide broad, simultaneous information to the market rather than to update the company’s formal financial statements.

Insights

Biotech pipeline and clinical development analyst

Silexion completes SIL204 toxicology, clearing a path toward Phase 2/3 in pancreatic cancer.

Silexion Therapeutics reports successful completion of toxicology studies for SIL204, an RNA silencing therapy candidate. Toxicology work evaluates safety in preclinical models and is an important prerequisite before starting advanced human trials such as a Phase 2/3 study in pancreatic cancer.

The mention of a Phase 2/3 clinical trial suggests the company is planning a study that both explores efficacy and could potentially support registration if results are strong, though no timing, design, or endpoints are described here. The information is furnished under Regulation FD, indicating it is intended as a broad pipeline progress update rather than a financial event.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Silexion Therapeutics (SLXN) announce about SIL204?

Silexion Therapeutics reported that it successfully completed toxicology studies for SIL204, its next-generation RNA silencing therapy candidate.

What is the next planned step for SIL204 mentioned by Silexion (SLXN)?

The company states that SIL204 is moving ahead of a Phase 2/3 clinical trial in pancreatic cancer, indicating plans for an advanced human study.

Which cancer indication is SIL204 targeting according to Silexion (SLXN)?

SIL204 is being developed for pancreatic cancer, as referenced in the press release title incorporated into the report.

On which exchange are Silexion Therapeutics shares and warrants traded?

Silexion’s ordinary shares trade on The Nasdaq Stock Market under the symbol SLXN, and its warrants trade under the symbol SLXNW.

How was the SIL204 update disclosed by Silexion Therapeutics (SLXN)?

The company furnished the information in a press release dated November 25, 2025, attached as Exhibit 99.1 and referenced under Regulation FD disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/25/2025 - 09:25 AM Learn about SEC filing dates

false000202241600-0000000972NASDAQNASDAQ00020224162025-11-252025-11-250002022416slxn:OrdinarySharesParValue00135PerShareMember2025-11-252025-11-250002022416slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf155250PerShareMember2025-11-252025-11-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 25, 2025

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands		001-42253		N/A
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

12 Abba Hillel Road Ramat-Gan, Israel		5250606
(Address of principal executive offices)		(Zip Code)

+972-3-756-4999

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.0135 per share		SLXN		The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $1,552.50 per share		SLXNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On November 25, 2025, Silexion Therapeutics Corp issued a press release entitled “Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer”. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits 

(d) Exhibits

99.1		Press Release dated November 25, 2025
104		Cover Page Interactive Data File (formatted in Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILEXION THERAPEUTICS CORP
Date: November 25, 2025	/s/ Ilan Hadar
	Name:	Ilan Hadar
	Title:	Chief Executive Officer